Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Hospira 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Hospira 4Q

In the Americas Pharmaceutical Specialty Injectables sales were $347.2 million in the quarter (-1%) and $1.3 billion for the year (+7%). Other Pharma revenue was $147.6 million in the quarter (-5%) and $522 million for the year (-5%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hospira

4Q Revenues: $913.7 million (-3%)

4Q Earnings: $155.7 million (+37%)

FY Revenues: $3.6 billion (+6%)

FY Earnings: $517.8 million (+71%)

Comments: In the Americas Pharmaceutical Specialty Injectables sales were $347.2 million in the quarter (-1%) and $1.3 billion for the year (+7%). Other Pharma revenue was $147.6 million in the quarter (-5%) and $522 million for the year (-5%). Devices Medication Management Systems revenue was $140.6 million (+9%) and $558.9 million for the year (+12%). Revenue decline in the quarter was driven by unfavorable foreign currency translation, high U.S. wholesaler purchasing patterns for Specialty Injectable Pharmaceuticals in 4Q07, and decreased demand among some contract manufacturing customers. Growth for the year was a result of the impact of new group purchasing organization (GPO) awards, and demand for the company’s MMS product lines, particularly its general infusion system, Symbiq. In the quarter, the company incurred charges of $9 million related to the closures of the Ashland, OH; Montreal, Canada; North Chicago, IL; and Morgan Hill, CA facilities; and Mayne Pharma integration and other acquisition-related charges of $2.8 million. The earnings increases are attributed to favorable volume/mix, improved manufacturing efficiency and the impact of SG&A cost-containment measures.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics